NXAQ
"NXAQ" is a word mark owned by Nxera Pharma Co., Ltd., filed at the USPTO on May 11, 2026. It is under examination and covers classes 9, 35, 42 and 44.
- Status
- Under examination
- Since August 28, 2026
- Filed
- May 11, 2026
- Registered
- Not yet
- Priority date
- November 11, 2025
- Claimed from United Kingdom
- Application no.
- 99816392
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 4 classes
Who owns NXAQ
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Nxera Pharma Co., Ltd.
Tokyo, Japan
Representative
Eric Lamb
Frost Brown Todd LLP
What the mark covers
The products and services NXAQ is filed for, grouped by Nice class.
Software, application software, computer software, computer software platforms, artificial intelligence, generative artificial intelligence software, generative design software, deep learning software, neural networks software and machine learning software, large language models software, frontier models software, foundation models software, retrieval augmented generation trained models software, knowledge graphs software; computer software for accessing, browsing and searching online databases; computer software for searching, tracking, modelling, exploration and analysis of data; artificial intelligence software for searching, tracking, modelling, exploration and analysis of data; databases; computer databases; data banks; electronic databases; interactive databases; data processing software; all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics
Business management, organisation and administration in the field of chemical products, biological products, pharmaceuticals, design and development of drugs, drug discovery; business management, organisation and administration in the field of research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; retail and wholesale services connected with the sale of pharmaceuticals, biological products and chemical and biological preparations; database management; computer database management; collection and compilation of data; compilation and systemisation of information and data in computer databases; compilation of information and data relating to life sciences, chemical and biological drug discovery, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics; data processing, systemisation and management; data processing services; providing business statistical information for use in predictive analytics and predictive modelling via computer databases; information, advisory and consultancy services relating to all of the aforesaid services
Drug and pharmaceutical discovery services; bio-technology, pharmaceutical, chemical and medical testing, research, development, advice, consultancy and information services; research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in chemical and biological drug discovery and development; research and development services for identifying lead chemical compounds; examination and research services in medicinal and synthetic chemistry; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; research, creation, development and provision of chemical and biological drug targets for screening purposes; research, analysis and examination for identification of compounds through automated screening processes; research and development services in chemical and biological pharmaceutical development; medical laboratory services; artificial intelligence as a service [AIaaS], software as a service, platform as a service [PaaS]; design and development of computer software; providing online non-downloadable computer software; providing online non-downloadable computer software for searching, tracking, modelling, exploration and analysis of data; computer programming; compilation of scientific information; preparation of scientific and technological reports; provision of scientific and technical information and data; information, advisory and consultancy services relating to all of the aforesaid services; all of the aforementioned being in the field of life sciences, chemical and biological drug discovery, molecular simulation, target identification, lead identification, pharmaceuticals, design and development of drugs, diagnostics and therapeutics
Pharmaceutical services; pharmaceutical advice and consultancy for medical purposes; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; research, creation, development and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid relating to drug discovery and use of G-protein-coupled receptors in the design and development of pharmaceutical products
What has happened so far
Steps recorded by the USPTO, newest first.
- Notification of non-final action e-mailed
- Non-final action e-mailed
- Non-final action written
- Assigned to examiner
- New application office supplied data entered
- Application filing receipt mailed
- New application entered
About NXAQ
Who owns the trademark "NXAQ"?
The USPTO trademark "NXAQ" (application 99816392) is owned by Nxera Pharma Co., Ltd.
What is the status of "NXAQ"?
Its status at the USPTO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull NXAQ and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019e2904-512c-71b2-ba5b-f6a403e7ae82
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019e2904-512c-71b2-ba5b-f6a403e7ae82",
"object": "trademark",
"mark_text": "NXAQ",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "US",
"application_number": "99816392",
"filing_date": "2026-05-11",
"nice_classes": [
9,
35,
42,
44
],
"owners": [
{
"name": "Nxera Pharma Co., Ltd.",
"entity_id": "ent_019ebaba-1670-77fd-a8ef-7433192214fd"
}
]
}